RAPT Therapeutics Inc Ordinary Shares RAPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RAPT is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
-
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold
-
RAPT Therapeutics' stock plunges as FDA halts two clinical trials
-
Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event
Trading Information
- Previous Close Price
- $8.56
- Day Range
- $8.12–8.47
- 52-Week Range
- $6.86–26.91
- Bid/Ask
- $8.10 / $8.14
- Market Cap
- $283.27 Mil
- Volume/Avg
- 322,803 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 131
- Website
- https://www.rapt.com
Comparables
Valuation
|
Metric
|
RAPT
|
VRDN
|
BMEA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.97 | 3.69 | 2.70 |
Price/Sales | — | 2,296.18 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RAPT
VRDN
BMEA
Financial Strength
|
Metric
|
RAPT
|
VRDN
|
BMEA
|
|---|---|---|---|
Quick Ratio | 7.28 | 17.93 | 7.74 |
Current Ratio | 7.41 | 18.26 | 7.84 |
Interest Coverage | — | −137.76 | — |
Quick Ratio
RAPT
VRDN
BMEA
Profitability
|
Metric
|
RAPT
|
VRDN
|
BMEA
|
|---|---|---|---|
Return on Assets (Normalized) | −45.28% | −42.76% | −56.31% |
Return on Equity (Normalized) | −50.94% | −82.42% | −65.70% |
Return on Invested Capital (Normalized) | −48.96% | −50.70% | −67.02% |
Return on Assets
RAPT
VRDN
BMEA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Csctllvgwd | Jdkm | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zslljysbs | Nqfdwg | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sbzksxxk | Zmknpr | $98.6 Bil | |
MRNA
| Moderna Inc | Rbcnhhc | Rbq | $41.0 Bil | |
ARGX
| argenx SE ADR | Glfhdlks | Wrn | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Rrlfgshq | Gtftc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vrbmkptn | Wphds | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nymdhrdn | Cszbww | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yjwvrrlfh | Kffvwx | $12.6 Bil | |
INCY
| Incyte Corp | Blynzmtw | Tpbchv | $12.0 Bil |